These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25477232)

  • 1. Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) project.
    Brodie SA; Li G; Brandes JC
    Respir Med; 2015 Jan; 109(1):131-6. PubMed ID: 25477232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer.
    Koga T; Takeshita M; Yano T; Maehara Y; Sueishi K
    Int J Cancer; 2011 Mar; 128(5):1009-17. PubMed ID: 20473935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
    Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
    Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.
    Takeshita M; Koga T; Takayama K; Yano T; Maehara Y; Nakanishi Y; Sueishi K
    Cancer Biol Ther; 2010 Nov; 10(9):933-41. PubMed ID: 20855974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHFR aberrant methylation involves a subset of human lung adenocarcinoma associated with poor clinical outcomes.
    Koga T; Takeshita M; Ijichi K; Yano T; Maehara Y; Sueishi K
    Hum Pathol; 2013 Jul; 44(7):1382-90. PubMed ID: 23415374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
    Pillai RN; Brodie SA; Sica GL; Shaojin Y; Li G; Nickleach DC; Yuan L; Varma VA; Bonta D; Herman JG; Brock MV; Ribeiro MJ; Ramalingam SS; Owonikoko TK; Khuri FR; Brandes JC
    Clin Cancer Res; 2013 Mar; 19(6):1603-11. PubMed ID: 23386692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
    Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
    Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
    Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
    Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancer.
    Guo M; Alumkal J; Drachova T; Gao D; Marina SS; Jen J; Herman JG
    Discov Med; 2015 Mar; 19(104):151-8. PubMed ID: 25828518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
    Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
    J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
    Bell DW; Lynch TJ; Haserlat SM; Harris PL; Okimoto RA; Brannigan BW; Sgroi DC; Muir B; Riemenschneider MJ; Iacona RB; Krebs AD; Johnson DH; Giaccone G; Herbst RS; Manegold C; Fukuoka M; Kris MG; Baselga J; Ochs JS; Haber DA
    J Clin Oncol; 2005 Nov; 23(31):8081-92. PubMed ID: 16204011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer.
    Mariatos G; Bothos J; Zacharatos P; Summers MK; Scolnick DM; Kittas C; Halazonetis TD; Gorgoulis VG
    Cancer Res; 2003 Nov; 63(21):7185-9. PubMed ID: 14612512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
    Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
    J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic classification of lung cancer: toward a personalized treatment.
    Mlika M; Laabidi S; Afrit M; Boussen H; El Mezni F
    Tunis Med; 2015 Jun; 93(6):339-44. PubMed ID: 26644092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor mutation in lung cancer are linked to bronchioloalveolar differentiation.
    Blons H; Côté JF; Le Corre D; Riquet M; Fabre-Guilevin E; Laurent-Puig P; Danel C
    Am J Surg Pathol; 2006 Oct; 30(10):1309-15. PubMed ID: 17001163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.
    Azuma K; Okamoto I; Kawahara A; Taira T; Nakashima K; Hattori S; Kinoshita T; Takeda M; Nakagawa K; Takamori S; Kuwano M; Ono M; Kage M
    J Thorac Oncol; 2012 Jan; 7(1):122-7. PubMed ID: 21892099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR and erbB2 mutation status in Japanese lung cancer patients.
    Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
    Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
    Mochinaga K; Tsuchiya T; Nagasaki T; Arai J; Tominaga T; Yamasaki N; Matsumoto K; Miyazaki T; Nanashima A; Hayashi T; Tsukamoto K; Nagayasu T
    Clin Lung Cancer; 2014 Mar; 15(2):136-144.e4. PubMed ID: 24405586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.